Latest Japan Approvals Include World-First For Pabinafusp
Other Nods For Vitrakvi, Polivy
A new batch of marketing authorizations in Japan includes new therapies for high-need cancer indications and rare diseases, and the first nod worldwide for a novel lysosomal disorder treatment that can address serious CNS symptoms.
You may also be interested in...
Deal Watch: Japan’s JCR Inks Pacts With Sumitomo Dainippon, Alexion
Agreement with Alexion is JCR’s first international deal for its blood-brain barrier drug delivery technology. Sartoris buys PolyPlus from private equity investors.
PRIME: EMA Says Yes To Only Three Of Twenty Hopefuls
The past few months have seen the European Medicines Agency award its much sought-after priority medicines designation to treatments for Hunter syndrome, bubble boy disease and narcolepsy.
Denali Sees Some Early Progress With Fusion Protein For Hunter Syndrome
Denali Therapeutics has reported promising early clinical data in Hunter syndrome for its fusion protein, DNL310, an investigational agent that crosses the blood-brain barrier and is expected to address disease-associated CNS effects; however, some biomarker data disappointed, and there are potential competitors also under development.